Fasenra granted Orphan Drug Designation by FDA
AstraZeneca’s Fasenra has been awarded Orphan Drug Designation in the US for the treatment of hypereosinophilic syndrome (HES).
Read More
Tag: ODD
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
